posted on 2014-06-12, 00:00authored byChenyu Ling, Liqiang Fu, Suo Gao, Wenjing Chu, Hui Wang, Yanqin Huang, Xiaoyan Chen, Yushe Yang
A series
of novel thioether pleuromutilin derivatives incorporating various
heteroaromatic substituents into the C14 side chain have been reported.
Structure–activity relationship (SAR) studies resulted in compounds 52 and 55 with the most potent in vitro antibacterial activity among
the series (MIC = 0.031–0.063 μg/mL). Further optimization
to overcome the poor water solubility of compound 55 resulted
in compounds 87, 91, 109, and 110 possessing good in vitro antibacterial activity with increased
hydrophilicity. Compound 114, the water-soluble phosphate
prodrug of compound 52, was also prepared and evaluated.
Among the derivatives, compound 110 showed moderate pharmacokinetic
profiles and good in vivo efficacy in both MSSA and MRSA systemic
infection models. Compound 110 was further evaluated
in CYP450 inhibition assay and displayed intermediate in vitro inhibition
of CYP3A4.